Vic Velanovich1, Ira Wollner. 1. Division of General Surgery, K-8, Henry Ford Hospital, Detroit, MI 48202, USA. vvelano1@hfhs.org
Abstract
BACKGROUND: To determine if pretreatment quality of life is associated with performance status in patients with pancreatic and periampullary tumors. METHODS: Eighty consecutive patients evaluated for surgical treatment of pancreatic or periampullary tumors completed the social functioning SF-36, a generic quality of life instrument. This instrument measures 8 domains of quality of life: physical functioning (PF), role-physical (RP), role-emotional, bodily pain, vitality, mental health, social functioning, and general health (GH). The best possible score is 100 and the worst possible score is 0. Each patient was then assigned a Karnofsky performance score (KPS), with the best possible score of 100 (normal, no complaints, no evidence of disease) and worst score of 0 (dead). Data recorded included age, gender, pathology, stage, resection, use of chemotherapy, and radiation therapy. Statistical analysis was done using single and multiple linear regression analysis, correlation coefficients (r) and coefficient of determination (r (2)). RESULTS: KPS was significantly associated with all domains of the SF-36 by single linear regression. By multiple linear regression, KPS was significantly associated with the PF domain (p < 0.001, r = 0.74), and nearly significantly associated with the RP (p = 0.07, r = 0.62) and GH (p = 0.06, r = 0.64) domains. This appears to be independent of tumor pathology and stage. CONCLUSION: The results imply that pretreatment quality of life and performance status are related concepts in patients with pancreatic and periampullary tumors. This is primarily true for the physical component of the SF-36. However, despite statistical significance, coefficients of determination (r (2) values) suggest that there are additional factors determining both quality of life and performance status in patients with pancreatic and periampullary tumors.
BACKGROUND: To determine if pretreatment quality of life is associated with performance status in patients with pancreatic and periampullary tumors. METHODS: Eighty consecutive patients evaluated for surgical treatment of pancreatic or periampullary tumors completed the social functioning SF-36, a generic quality of life instrument. This instrument measures 8 domains of quality of life: physical functioning (PF), role-physical (RP), role-emotional, bodily pain, vitality, mental health, social functioning, and general health (GH). The best possible score is 100 and the worst possible score is 0. Each patient was then assigned a Karnofsky performance score (KPS), with the best possible score of 100 (normal, no complaints, no evidence of disease) and worst score of 0 (dead). Data recorded included age, gender, pathology, stage, resection, use of chemotherapy, and radiation therapy. Statistical analysis was done using single and multiple linear regression analysis, correlation coefficients (r) and coefficient of determination (r (2)). RESULTS: KPS was significantly associated with all domains of the SF-36 by single linear regression. By multiple linear regression, KPS was significantly associated with the PF domain (p < 0.001, r = 0.74), and nearly significantly associated with the RP (p = 0.07, r = 0.62) and GH (p = 0.06, r = 0.64) domains. This appears to be independent of tumor pathology and stage. CONCLUSION: The results imply that pretreatment quality of life and performance status are related concepts in patients with pancreatic and periampullary tumors. This is primarily true for the physical component of the SF-36. However, despite statistical significance, coefficients of determination (r (2) values) suggest that there are additional factors determining both quality of life and performance status in patients with pancreatic and periampullary tumors.
Authors: Franck Bonnetain; Xavier Paoletti; Sandra Collette; Michel Doffoel; Olivia Bouché; Jean Luc Raoul; Philippe Rougier; Fadil Masskouri; Jean Claude Barbare; Laurent Bedenne Journal: Qual Life Res Date: 2008-07-10 Impact factor: 4.147
Authors: Stefano Crippa; Ismael Domínguez; J Ruben Rodríguez; Oswaldo Razo; Sarah P Thayer; David P Ryan; Andrew L Warshaw; Carlos Fernández-del Castillo Journal: J Gastrointest Surg Date: 2008-03-04 Impact factor: 3.452
Authors: Murielle E L Mauer; Martin J B Taphoorn; Andrew Bottomley; Corneel Coens; Fabio Efficace; Marc Sanson; Alba A Brandes; Carin C D van der Rijt; Hans J J A Bernsen; Marc Frénay; Cees C Tijssen; Denis Lacombe; Martin J van den Bent Journal: J Clin Oncol Date: 2007-12-20 Impact factor: 44.544
Authors: Andrew Bottomley; Corneel Coens; Fabio Efficace; Rabab Gaafar; Christian Manegold; Sjaak Burgers; Mark Vincent; Catherine Legrand; Jan P van Meerbeeck Journal: J Clin Oncol Date: 2007-12-20 Impact factor: 44.544
Authors: M Mauer; R Stupp; M J B Taphoorn; C Coens; D Osoba; C Marosi; R Wong; O de Witte; J G Cairncross; F Efficace; R O Mirimanoff; P Forsyth; M J van den Bent; M Weller; A Bottomley Journal: Br J Cancer Date: 2007-07-03 Impact factor: 7.640
Authors: Thomas M Atkinson; Charissa F Andreotti; Kailey E Roberts; Rebecca M Saracino; Marisol Hernandez; Ethan Basch Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603
Authors: Jasvinder A Singh; Daniel Satele; Suneetha Pattabasavaiah; Jan C Buckner; Jeff A Sloan Journal: Health Qual Life Outcomes Date: 2014-12-18 Impact factor: 3.186